| Autor: | Begoña Mellado, J Estapé, Nuria Viñolas, L. Caralt, Francesc Graus |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Cisplatin
Cancer Research medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment Neutropenia medicine.disease Gastroenterology Metastasis Surgery Breast cancer Neurology Oncology Internal medicine medicine Neurology (clinical) business Lung cancer Survival rate Etoposide medicine.drug |
| Zdroj: | Journal of Neuro-Oncology. 35:145-148 |
| ISSN: | 0167-594X |
| DOI: | 10.1023/a:1005835430489 |
| Popis: | Fourteen patients with brain metastases (BM) of solid tumors received intravenous cisplatinum, 40 mg/m2/day and etoposide, 150 mg/m2/day, for 3 days every 3 weeks. Primary tumors were lung (8 patients), breast (4), colon (1), and stomach (1). Two patients responded (1 complete response in a poorly differentiated lung cancer patient and 1 partial response in a breast cancer patient). The overall response rate was 14%, with a median survival of 6 months. Main toxicity was grade 3-4 neutropenia that occurred in 36% of patients. There were no toxic-related deaths. Chemotherapy as a single therapeutic regimen seems not to be an effective treatment for BM from relatively resistant solid tumors. Moreover, it produces rather high, although not life-threatening, hematologic toxicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink